Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: https://www.innoventbio.com/
223 articles about Innovent Biologics
-
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
-
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
3/1/2022
AnHeart Therapeutics (“AnHeart”), together with Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), today jointly announce that the Center for Drug Evaluation (CDE) of China’s Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to taletrectinib.
-
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
2/28/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), together with AnHeart Therapeutics ("AnHeart"), today jointly announced that the Center for Drug Evaluation (CDE) of China's Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to taletrectinib.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
2/23/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today announces that the first patient has been successfully dosed in the phase 1, first-in-human clinical trial of its proprietary CD73 antibody (development code: IBI325) in patients with advanced solid tumor.
-
Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345
2/21/2022
Innovent Biologics, Inc. announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T cell product for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-initiated-trial.
-
By the end of the CREDIT-1 study, patients experienced a significant reduction in low-density lipoprotein cholesterol compared to the placebo group.
-
Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint
2/16/2022
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces that the primary endpoint was met in two Chinese registration studies of recombinant full-human anti-PCSK-9 monoclonal antibody.
-
The unspoken challenge is: how diverse can a trial run in the United States really be right now?
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
2/14/2022
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to their fully human anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
2/14/2022
Innovent Biologics, Inc. together with IASO Biotherapeutics jointly announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has formally granted Orphan Drug Designation to their co-developed fully-human B-cell maturation antigen -targeted chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.
-
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
-
It's not likely that the FDA will give the cancer drug sintilimab immediate attention, since the research was conducted exclusively in China.
-
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
1/24/2022
Innovent Biologics, Inc. announced that the Hong Kong Department of Health (DH) has approved Pemazyre®.
-
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma.
1/21/2022
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), today jointly announced with Eli Lilly and Company ("Lilly", NYSE: LLY) the final clinical outcome and biomarker analysis of the open label, phase Ib study (NCT04072679) of sintilimab plus bevacizumab biosimilar injection for advanced hepatocellular carcinoma.
-
Amagma Therapeutics announced a licensing agreement with Innovent Biologics for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC Platform.
-
Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.
-
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
12/24/2021
Innovent Biologics, Inc. today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for sintilimab plus bevacizumab biosimilar injection.
-
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
12/13/2021
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.